Abstract:The protein-protein interactions (PPIs) in the biological systems are important to maintain a number of cellular processes. Several disorders including cancer may be developed due to dysfunction in the assembly of PPI networks. Hence, targeting intracellular PPIs can be considered as a crucial drug target for cancer therapy. Among the enormous and diverse group of cancer-enabling PPIs, the Hsp90-Cdc37 is prominent for cancer therapeutic development. The successful inhibition of Hsp90-Cdc37 PPI interface can be an important therapeutic option for cancer management. In the current study, a set of more than sixty thousand compounds belong to four databases were screened through a multi-steps molecular docking study in Glide against the Hsp90-Cdc37 interaction interface. The Glide-score and Prime-MM-GBSA based binding free energy of DCZ3112, standard Hsp90-Cdc37 inhibitor were found to be -6.96 and -40.46 kcal/mol, respectively. The above two parameters were used as cut-off score to reduce the chemical space from all successfully docked molecules. Furthermore, the in-silico pharmacokinetics parameters, common-feature pharmacophore analyses and the molecular binding interactions were used to wipe out the inactive molecules. Finally, four molecules were found to be important to modulate the Hsp90-Cdc37 interface. The potentiality of the final four molecules was checked through several drug-likeness characteristics. The molecular dynamics (MD) simulation study explained that all four molecules retained inside the interface of Hsp90-Cdc37. The binding free energy of each molecule obtained from the MD simulation trajectory was clearly explained the strong affection towards the Hsp90-Cdc37. Hence, the proposed molecule might be crucial for successful inhibition of the Hsp90-Cdc37 interface.Communicated by Ramaswamy H. Sarma.

Small-molecule Inhibitor Targeting the Hsp90-Cdc37 Protein-Protein Interaction in Colorectal Cancer

Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (hsp90) and Cell Division Cycle 37 As Orally Active Inhibitors for the Treatment of Colorectal Cancer.

Design, Synthesis and Bioevaluation of Inhibitors Targeting HSP90-CDC37 Protein-Protein Interaction Based on a Hydrophobic Core.

Discovery of a Covalent Inhibitor of Heat Shock Protein 90 with Antitumor Activity That Blocks the Co-Chaperone Binding Via C-terminal Modification.

Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function

Allosteric CDC37 Inhibitor Disrupts Chaperone Complex to Block CDK4/6 Maturation

Discovery of Second Generation Heat Shock Protein 110 (HSP110) Inhibitors for Potential Treatment of Colorectal Cancer

Rational design of peptide inhibitors targeting HSP90–CDC37 protein–protein interaction

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery

Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.

In silico identification of small molecule modulators for disruption of Hsp90-Cdc37 protein-protein interaction interface for cancer therapeutic application

Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer

Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor.

Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs As Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening.

Hsp90 Is A Novel Target Molecule Of Cddo-Me In Inhibiting Proliferation Of Ovarian Cancer Cells

Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.

Inhibition of Gastric Tumor Growth by a Novel Hsp90 Inhibitor

Allosteric Regulation of Hsp90α's Activity by Small Molecules Targeting the Middle Domain of the Chaperone.

Optimization and Bioevaluation of Cdc37-derived Peptides: an Insight into Hsp90-Cdc37 Protein-Protein Interaction Modulators.

Discovery and Identification of Cdc37-derived Peptides Targeting the Hsp90–Cdc37 Protein–protein Interaction

DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer